Discontinued drugs in 2008: Cardiovascular drugs

Expert Opinion on Investigational Drugs

Volumn 18, Issue 7, 2009, Pages 875-885

  Zhang, Xu Song ^a   Xiang, Bing Ren ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

AGI 1067; Alfimeprase; DITPA; DZ 697b; ET 216; ET 642; Ilepatril; Lercanidipine MeltDose; LY 517717; MK 8141; PF 3392455; Rotigaptide; SL 65.0472; SR 123781; Tezosentan; Torasemide ER Penwest

Indexed keywords

AC 610612; ALFIMEPRASE; ANTITHROMBOCYTIC AGENT; AVE 7688; CARDIOVASCULAR AGENT; DITPA; DZ 697B; ENKEPHALINASE INHIBITOR; ET 216; ET 642; HEPARIN DERIVATIVE; ILEPATRIL; LERCANIDIPINE; MK 8141; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PF 3392455; PROBUCOL SUCCINATE; PW 2132; RENIN INHIBITOR; ROTIGAPTIDE; SEROTONIN 1B ANTAGONIST; SEROTONIN 2A ANTAGONIST; SL 650472; SR 123781; TEZOSENTAN; THYROID HORMONE; TORASEMIDE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ATHEROSCLEROSIS; ATHEROTHROMBOSIS; CATHETER OCCLUSION; CLINICAL TRIAL; DATA BASE; DIABETIC NEPHROPATHY; DIASTOLIC DYSFUNCTION; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; EDEMA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; KIDNEY FAILURE; MICROANGIOPATHY; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RESTENOSIS; REVIEW; STABLE ANGINA PECTORIS; STROKE; THROMBOSIS; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VENOUS CATHETER OCCLUSION; VENOUS THROMBOEMBOLISM;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; PHARMACOLOGY, CLINICAL; TIME FACTORS;

EID: 67650422376     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903020308     Document Type: Review

References (8)

1. Czerepak EA, Ryser S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov 2008;7:197-8
2. Zhang XS, Xiang BR. Discontinued drugs in 2007: cardiovascular drugs. Expert Opin Investig Drugs 2008;7(12):1817-28
3. Spooner PH, Thai HM, Goldman S, et al. Thyroid hormone analog, DITPA, improves endothelial nitric oxide and beta-adrenergic mediated vasorelaxation after myocardial infarction. J Cardiovasc Pharmacol 2004;44(4):453-9
4. Leitzbach D, Afkham F, Schäfer S, et al. Improvement of systolic and diastolic function in old SHR by long-term treatment with the new vasopeptidase inhibitor AVE7688 and the ACE inhibitor ramipril [abstract]. Hypertension 2003;42(4):643
5. GAP-134/ZP1609 programme. Zealand Pharma product pipeline information. Available from: http://www.zealandpharma.com/ Product-Pipeline/GAP-134-ZP1609 [Last accessed 22 April 2009]
6. Actelion announces first quarter 2008 financial results, published 22 April 2008. Available from: http://www1.actelion.com/ en/journalists/news- archive.page? newsId = 1211488 [Last accessed 22 April 2009]
7. Schäfer S, Kolkhof P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today 2008;13(21/22):913-6
8. The Pharmaprojects Database, Informa UK plc. Available from: http://www.pharmaprojects.com [Last accessed 2009 March]